Dementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia
|
|
- Theodore Hood
- 5 years ago
- Views:
Transcription
1 Dementia: A Comprehensive Update 2016 Neuroimaging, CSF, and genetic biomarkers in dementia Bradford C. Dickerson, M.D. Associate Professor of Neurology, Harvard Medical School Departments of Neurology and Psychiatry Alzheimer s Disease Research Center & Frontotemporal Dementia Unit Massachusetts General Hospital Martinos Center for Biomedical Imaging bradd@nmr.mgh.harvard.edu
2 Progression of Alzheimer s Disease: similar model for many other diseases Presymptomatic Prodromal Cognitive Function Clinical Dementia Mild Probable Cognitive Alzheimer s Impairment Disease Accumulating pathology Disease Progression
3 Roles of biomarkers in dementia: Clinical practice, 2016 Clinical Status Symptoms Signs Brain Anatomy Brain Physiology CT/MRI: Identification of regional atrophy Brain Pathology SPECT/FDG-PET: Identification of regional reductions in function CT/MRI: Indicators of brain pathology CSF biomarkers Molecular imaging
4 April 2011: New diagnostic criteria for Alzheimer s Disease Preclinical AD MCI: High likelihood AD AD Dementia Cognitive Function Mild Probable Cognitive Alzheimer s Impairment Disease Biomarkers consistent with AD pathophysiology Accumulating pathology Disease Progression
5 Illustrative cases Case 1 72yo with gradually progressive impairment of memory, orientation, and judgement and problem-solving; neuropsych testing showed amnesia, executive dysfunction, and visuospatial impairment Case 2 54yo with gradually progressive changes in judgment and decision-making, social and interpersonal behavior, and language; neuropsych testing showed executive dysfunction, anomia with sparing of memory and visuospatial function Case 3 52yo with gradually progressive difficulties with judgement and problem-solving and high-level verbal skills, lack of insight; neuropsych testing showed executive dysfunction with sparing of memory, language, and visuospatial function
6 Roles of biomarkers in dementia: Clinical practice, 2016 Clinical Status Symptoms Signs Brain Anatomy Brain Physiology CT/MRI: Identification of brain pathology Brain Pathology
7 Structural measures of pathology or abnormal neuroanatomy in dementias Identification of contributors to cognitive/ behavioral impairment A variety of types of brain pathology can cause various forms of dementia, including cerebrovascular disease, tumor, and other lesions These are relatively uncommon in typical cases but should be surveyed Identification of changes consistent with neurodegeneration Careful visual inspection of clinical anatomical brain MRI can reveal patterns consistent with specific neurodegenerative diseases
8 Cerebrovascular disease CT MRI-FLAIR MRI-T2 O Brien et al, Adv Psych Tr 6:109-19;2000
9 Normal Pressure Hydrocephalus dementia, ataxia, incontinence SAH/meningitis history? enlarged ventricles out of proportion to sulci relatively uncommon surgical management? efficacy is controversial
10 Creutzfeld-Jacob Disease 9 weeks 51 y/o woman with rapidly progressive cognitive impairment and gait ataxia, developed intermittant jerking motions of both arms and legs, and expired 4 months after the first symptoms developed.
11 Creutzfeld-Jacob Disease 53 y/o man with rapidly progressive cognitive impairment
12 Roles of biomarkers in dementia: Clinical practice, 2016 Clinical Status Symptoms Signs Brain Anatomy Brain Physiology CT/MRI: Identification of regional atrophy Brain Pathology
13 Alzheimer s Disease: MTL & temporoparietal atrophy
14 Alzheimer s Disease: MTL & temporoparietal atrophy
15 Alzheimer s Disease: MTL & temporoparietal atrophy
16 FTD: Frontal & anterior temporal atrophy (spares parietal)
17 PPA--semantic: Left anterior temporal
18 PPA--nonfluent: Left frontoinsular atrophy (spares temporal)
19 PPA: Left anterior temporal atrophy (spares frontal)
20 Posterior Cortical Atrophy: Parietal atrophy
21 PCA: Parietal atrophy (spares temporal)
22 PCA: Parietal atrophy (spares frontal)
23 PCA: Parietal atrophy (spares frontal)
24 Progressive supranuclear palsy: Midbrain atrophy PD PSP MSA-P Oba H et al., Neurology 2005
25 Use of Volumetrics in the Clinic
26 Roles of biomarkers in dementia: Clinical practice, 2016 Clinical Status Symptoms Signs Brain Anatomy Brain Physiology Brain Pathology FDG-PET/SPECT: Identification of regional reductions in function
27 FDG-PET: glucose metabolism major use in clinical dementia: AD vs. FTD Normal Aging Alzheimer s FTD
28 Aging, MCI, AD: FDG-PET Cognitively intact older adult Mild Cognitive Impairment Alzheimer s Disease
29 FDG-PET: glucose metabolism: DLB, CBD CBD Normal temporoparietal, occipital metabolism DLB Temporoparietal hypometabolism, occipital hypometabolism
30 FDG-PET: glucose metabolism: DLB, CBD CBD Asymmetric perirolandic (posterior frontal, anterior parietal) hypometabolism DLB Temporoparietal hypometabolism, occipital hypometabolism
31 FDG- PET in Normal Aging, MCI, AD, and FTD NL MCI pad ftd NL = normal; pad = prodromal Alzheimer s disease; ftd = frontotemporal demenla. AD- demenla Cog NL APOE4 carriers
32 Roles of biomarkers in dementia: Clinical practice, 2016 Clinical Status Symptoms Signs Brain Anatomy Brain Physiology Brain Pathology SPECT/PET: Measures of neurotranmitter system function CSF biomarkers (Molecular imaging)
33 Amyloid imaging with PET Pittsburgh Compound-B (PIB) Alzheimer s disease Normal aging
34
35 Presymptomatic Alzheimer s Disease Amyloid imaging with PET 55 y/o PS1 Carrier DM 60 y/o Normal Control
36 F18 Amyloid Imaging Tracers Flutemetamol1 Florbetapir2 AD NL F- 18 Amyloid Tracers Florbetaben3 Navidea NAV46944 AD NL 1. Vandenberghe R et al. Ann Neurol. 2010;68: Barthel H et al. Lancet Neurol. 2011;10: Wong DF et al. J Nucl Med. 2010;51: Chen K et al. Alzheimers Dement. 2012;8(4 suppl):p14(abstract IC- P- 011).
37 Amyloid Imaging Correlates With Amyloid Pathology F18-AV-45 PET Visual Read AV45 SUVr Amyloid Staining (4G8 antibody) Amyloid Burden (Quant IHC) (%) Neuropathologic Diagnosis MCI Normal brain AD Tangles only PDD AD with cortical Lewy bodies AD AD AD AD AD AD SUVr = standard uptake value ralo; PDD = Parkinson s disease demenla; HC = healthy control. Fleisher AS. Neurology. 2009;74(9, suppl 2);abstract 1165AAN1OD1. Clark CM et al. JAMA. 2011;305:
38 InterpreLng Amyloid PET Scans Negative Positive A A C D C D B B Amyvid florbetapir F 18 injeclon prescribing informalon. Eli Lilly and Company, Indianapolis, IN, revised Available at hgp://pi.lilly.com/ us/amyvid- uspi.pdf
39 Jansen WJ, JAMA, 2015
40 Amyloid Imaging Taskforce Appropriate- Use Criteria Amyloid imaging is appropriate in the following situalons. 1. A cogni6ve complaint with objec6vely confirmed impairment 2. Performed only aber full standard workup is completed Structured clinical evalua6on with objec6ve neurocogni6ve tes6ng Structural brain imaging Relevant laboratory tests 3. AD is a possible diagnosis, but it is uncertain. 4. Knowledge of Aβ pathology would increase diagnos6c certainty and alter management. 5. Should only be ordered by experts in demen6a Specialty training and a prac6ce with 25% demen6a care Geriatric/behavioral psychiatry and neurology Johnson KA et al. Alzheimers Dement Jan;9:e1- e16. Johnson KA et al. J Nucl Med. 2013;54:
41 Inappropriate Use of Amyloid PET Imaging Amyloid PET imaging is inappropriate: 1. For evalua6on of individuals without cogni6ve complaints; however, preclinical AD may become an indica6on for amyloid Imaging if preven6ve treatments are proved to be effec6ve. 2. When standard recommended clinical diagnos6c tes6ng has not been ordered for ini6al assessment. 3. As a stand- alone diagnos6c for AD demen6a. 4. To assess disease progression. Johnson KA et al. Alzheimers Dement. 2013;9:e1- e16. Johnson KA et al. J Nucl Med. 2013;54:
42 Imaging DemenLa Evidence for Amyloid PET Scanning: IDEAS Study study.org ParLcipants: 18,488 Medicare beneficiaries mee6ng specific AUC* enrolled over 24 months at US sites as part of a CMS CED research program. Aim 1: assess impact of amyloid PET on short- term pa6ent management. Aim 2: compare medical outcomes at 12 months for pa6ents enrolled in the study with a matched control cohort of pa6ents who have never undergone amyloid PET. based on Medicare claims data imaging *Amyloid PET should only be considered in palents with clear, measurable cognilve deficits when there is substanlal diagnoslc uncertainty amer a comprehensive evalualon by a demenla specialist); AUC = appropriate use criteria; CMS = Centers for Medicare & Medicaid Services; CED = Coverage with Evidence Development. Johnson KA et al. Alzheimers Dement. 2013;9:e1- e16.
43 Tau PET Imaging (11C- PBB3) Maruyama M et al. Neuron. 2013;79:
44 Dopaminergic Function (DAT) AD Parkinson s Disease DLB
45 Cerebrospinal fluid markers Alzheimer s Disease Abeta 1-42 reduced in AD Total-tau elevated in AD as well as other disorders Phospho-tau elevated specifically in AD Other neurodegenerative disorders FTD DLB
46 Illustrative cases Case 1 72yo with gradually progressive impairment of memory, orientation, and judgement and problem-solving; neuropsych testing showed amnesia, executive dysfunction, and visuospatial impairment Case 2 54yo with gradually progressive changes in judgment and decision-making, social and interpersonal behavior, and language; neuropsych testing showed executive dysfunction, anomia with sparing of memory and visuospatial function Case 3 52yo with gradually progressive difficulties with judgement and problem-solving and high-level verbal skills, lack of insight; neuropsych testing showed executive dysfunction with sparing of memory, language, and visuospatial function
47 Case 1
48 Illustrative cases Case 1 72yo with gradually progressive impairment of memory, orientation, and judgement and problem-solving; neuropsych testing showed amnesia, executive dysfunction, and visuospatial impairment Case 2 54yo with gradually progressive changes in judgment and decision-making, social and interpersonal behavior, and language; neuropsych testing showed executive dysfunction, anomia with sparing of memory and visuospatial function Case 3 52yo with gradually progressive difficulties with judgement and problem-solving and high-level verbal skills, lack of insight; neuropsych testing showed executive dysfunction with sparing of memory, language, and visuospatial function
49 Case 2
50 Case 2
51 A CSF amyloid- β level B CSF tau level
52 CSF amyloid- β level (pg/ml) Consistent with AD pathology Aβ = 255; bau = 459; ptau = 77 CSF tau level (pg/ml)
53 Illustrative cases Case 1 72yo with gradually progressive impairment of memory, orientation, and judgement and problem-solving; neuropsych testing showed amnesia, executive dysfunction, and visuospatial impairment Case 2 54yo with gradually progressive changes in judgment and decision-making, social and interpersonal behavior, and language; neuropsych testing showed executive dysfunction, anomia with sparing of memory and visuospatial function Case 3 52yo with gradually progressive difficulties with judgement and problem-solving and high-level verbal skills, lack of insight; neuropsych testing showed executive dysfunction with sparing of memory, language, and visuospatial function
54 Case 3 FDG-PET PiB-PET
55 Genetic testing What genes? Early onset AD (PS1 >> PS2, APP) FTD (MAPT, PGRN, C9ORF, FUS) Whom to test? How to perform testing
56 Case example 39 y female with 2 year history of gradually progressive dementia Predominantly executive dysfunction, lesser degree of memory impairment Father with clinical diagnosis of Pick s disease, onset in early 50s, died at 57, no autopsy
57 39y female Relatively mild MTL atrophy
58 39y female Prominent temporoparietal atrophy
59 Temporoparietal hypometabolism 39y female: FDG-PET
60 Case example 39 y female with 2 year history of gradually progressive dementia Predominantly executive dysfunction, lesser degree of memory impairment Father with clinical diagnosis of Pick s disease, onset in early 50s, died at 57, no autopsy Genetic testing revealed mutation in Presenilin 1 Autopsy (age 44) revealed AD pathology
61 Williamson J et al., Neurologist, 2009
62 Roles of biomarkers in dementia evaluation: Clinical practice, 2016 Routine MRI Important first step to evaluate for various forms of pathology High-resolution MRI with thin coronal cuts Useful for identifying specific atrophy patterns Functional brain studies: FDG-PET or SPECT Differential diagnosis of AD vs. FTD Useful for identifying many other patterns In the eye of the beholder : Look at your scans personally! CSF study: To evaluate for evidence of AD pathobiology Genetic testing: For diagnostic purposes particularly in early onset dementias
63 Looking ahead: Future uses of biomarkers in neurodegenerative diseases Early diagnosis of mildly symptomatic individuals More confident diagnosis of atypical cases Risk assessment in asymptomatic individuals? Identification of candidates for clinical trials Predicting effects of treatment Monitoring of effects of treatment
64 Progression of neurodegenerative diseases Presymptomatic Prodromal Neurologic Function Clinical Disease Disease Progression
65 Progression of neurodegenerative diseases Presymptomatic Prodromal Neurologic Function Clinical Disease Accumulating pathology Disease Progression
66 Progression of neurodegenerative diseases Presymptomatic Prodromal Regional brain volume Neurologic Function Clinical Disease Accumulating pathology Disease Progression
67 Progression of neurodegenerative diseases Presymptomatic Prodromal Regional brain volume Hypometabolism Neurologic Function Clinical Disease Accumulating pathology Disease Progression
68 Progression of neurodegenerative diseases Presymptomatic Prodromal Neurologic Function Diseasemodifying therapy Clinical Disease Accumulating pathology Disease Progression
69 Progression of neurodegenerative diseases Presymptomatic Prodromal Neurologic Function Diseasemodifying therapy Clinical Disease Disease Progression
70 Progression of neurodegenerative diseases Presymptomatic Prodromal Neurologic Function Diseasemodifying therapy Clinical Disease Disease Progression
71 Progression of neurodegenerative diseases Presymptomatic Prodromal Neurologic Function Diseasemodifying therapy Clinical Disease Disease Progression
72 Thanks! Support National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Institute of Mental Health, Alzheimer s Association,
Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationUpdate on functional brain imaging in Movement Disorders
Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More informationRound table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation
Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation 1. Reflection of Mild Cognitive Impairment (MCI) and Dementias by Molecular Imaging, PET
More informationYin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre
Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5
More information! slow, progressive, permanent loss of neurologic function.
UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationreview of existing studies on ASL in dementia Marion Smits, MD PhD
review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam
More informationDiagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16
The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei
More informationRanjan Duara, MD, FAAN
Ranjan Duara, MD, FAAN Medical Director, Wien Center for Alzheimer s Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach Clinical Professor of Neurology, Herbert Wertheim College of Medicine,
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationFDG-PET e parkinsonismi
Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism
More informationImaging in Dementia:
Imaging in Dementia: Options for Clinical Practice 2017 John A. Bertelson, MD Clinical Chief of Neurology, Seton Brain and Spine Institute Assistant Professor of Medicine, Dell Medical School, UT Austin
More informationDiagnosing Dementia: Signs & symptoms, differential diagnosis of common dementias, and non-degenerative memory loss
Diagnosing Dementia: Signs & symptoms, differential diagnosis of common dementias, and non-degenerative memory loss Incidence of Common Neurological Diseases Incidence New Cases Disease (per 100,000) (per
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationThe frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer
The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer MRC Clinician Scientist Honorary Consultant Neurologist Dementia Research Centre, UCL Institute of Neurology
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationForm A3: Subject Family History
Initial Visit Packet NACC Uniform Data Set (UDS) Form A: Subject Family History ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by a clinician
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More information3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion
Alzheimer s and Dementia Research: An Advanced Discussion Brad Boeve, MD Department of Neurology Mayo Clinic Alzheimer s and Dementia Research: An Advanced Discussion Theoretical Constructs in Aging/Dementia
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationClinical Genetics & Dementia
Clinical Genetics & Dementia Dr Nayana Lahiri Consultant in Clinical Genetics & Honorary Senior Lecturer Nayana.lahiri@nhs.net Aims of the Session To appreciate the potential utility of family history
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationNIH Public Access Author Manuscript Semin Neurol. Author manuscript; available in PMC 2014 November 14.
NIH Public Access Author Manuscript Published in final edited form as: Semin Neurol. 2013 September ; 33(4): 386 416. doi:10.1055/s-0033-1359312. Neuroimaging Biomarkers of Neurodegenerative Diseases and
More informationDementia Past, Present and Future
Dementia Past, Present and Future Morris Freedman MD, FRCPC Division of Neurology Baycrest and University of Toronto Rotman Research Institute, Baycrest CNSF 2015 Objectives By the end of this presentation,
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationObjectives. Objectives continued: 3/24/2012. Copyright Do not distribute or replicate without permission 1
Frontotemporal Degeneration and Primary Progressive Aphasia Caregiver and Professional Education Conference Diana R. Kerwin, MD Assistant Professor of Medicine-Geriatrics Cognitive Neurology and Alzheimer
More informationUCSF Memory and Aging Center 2016
UCSF Memory and Aging Center 2016 Best Practices in Mild Cognitive Impairment & Dementia Bruce L. Miller, MD A.W. and Mary Margaret Clausen Distinguished Professor in Neurology Director, Memory and Aging
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationProvider Led Entity. CDI Quality Institute PLE Neurocognitive Disorders AUC 02/05/2019
Provider Led Entity CDI Quality Institute PLE Neurocognitive Disorders AUC 02/05/2019 Appropriateness of advanced imaging procedures* in patients with a suspected neurocognitive disorder: *Including MRI,
More informationI do not have any disclosures
Alzheimer s Disease: Update on Research, Treatment & Care Clinicopathological Classifications of FTD and Related Disorders Keith A. Josephs, MST, MD, MS Associate Professor & Consultant of Neurology Mayo
More informationClaims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association
Claims & Underwriting Alzheimer s & Cognitive Impairment: You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association 1 OVERVIEW Impact
More informationPart 2: Early detection, assessment and treatment in relation to the new guidelines. Christopher Patterson McMaster University
Part 2: Early detection, assessment and treatment in relation to the new guidelines Christopher Patterson McMaster University C. Patterson MD, FRCPC Division of Geriatric Medicine, McMaster University
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationRe: Proposed Decision Memo for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N)
1300 North 17 th Street Suite 1752 Arlington, Virginia 22209 Tel: 703.841.3200 Fax: 703.841.3392 www.medicalimaging.org July 26, 2013 By electronic mail Louis Jacques, MD Director Coverage and Analysis
More informationLa neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali
La neurosonologia Nelle patologie degenerative e vascolari cerebrali Andrea Pilotto Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative Prof. Daniela Berg Department of Neurodegeneration
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationDEMENTIA 9/29/16. Introduction. Introduction. Signs and Symptom. Epidemiology. Dementia. Dr. Yotin Chinvarun M.D. Ph.D.
Introduction DEMENTIA Dr. Yotin Chinvarun M.D. Ph.D. Neurology, Pramongkutklao hospital In 1901 Auguste Deter, a woman in her early 50s, became 1 st person diagnosed with Alzheimer's disease, a form of
More informationImaging biomarkers for Parkinson s disease
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 6 MDS-ES/EAN: Neuroimaging in movement disorders - Level 2 Imaging biomarkers for Parkinson
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More information212 Index C-SB-13,
Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration
More informationSandra Weintraub, PhD Clinical Core Leader and Professor
Sandra Weintraub, PhD Clinical Core Leader and Professor Northwestern Cognitive Neurology and Alzheimer s Disease Center (CNADC) Chicago, Illinois www.brain.northwestern.edu Why is it so difficult to diagnose
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationDementia. Amber Eker, MD. Assistant Professor Near East University Department of Neurology
Dementia Amber Eker, MD Assistant Professor Near East University Department of Neurology Dementia An acquired syndrome consisting of a decline in memory and other cognitive functions Impairment in social
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationVisual Dysfunction in Alzheimer s Disease and Parkinson s Disease
Visual Dysfunction in Alzheimer s Disease and Parkinson s Disease Victoria S. Pelak, MD Professor of Neurology and Ophthalmology Divisions of Neuro-ophthalmology and Behavioral Neurology University of
More informationPerspectives on Frontotemporal Dementia and Primary Progressive Aphasia
Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia Bradley F. Boeve, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Alzheimer s Disease
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationFTD basics! Etienne de Villers-Sidani, MD!
FTD basics! Etienne de Villers-Sidani, MD! Frontotemporal lobar degeneration (FTLD) comprises 3 clinical syndromes! Frontotemporal dementia (behavioral variant FTD)! Semantic dementia (temporal variant
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationRecommendations for the Diagnosis and Treatment of Dementia 2012
Recommendations for the Diagnosis and Treatment of Dementia 2012 Based on the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (4 th CCCDTD) 2012 Gauthier S, Patterson C, Chertkow
More informationThe Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease
The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease AIBL: Two site collaborative study Study is conducted at two sites: Perth
More informationIl processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D.
Il processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D. Professor of Clinical Neurosciences, University of Geneva Médecin Responsable, Memory Clinic, Hôpitaux Universitaires
More informationDo not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009
Sandra Weintraub, Ph.D. Clinical Core Director, Cognitive Neurology and Alzheimer s Disease Center Northwestern University Feinberg School of Medicine Chicago, Illinois Dementia: a condition caused by
More informationEarly Onset Dementia From the background to the foreground
Early Onset Dementia From the background to the foreground Dr Jeremy Isaacs Consultant Neurologist St George s Hospital Excellence in specialist and community healthcare Themes of my talk The early onset
More informationDifferential Diagnosis
Differential Diagnosis 2 2.1 Introduction AD accounts for up to 75 % of all dementia cases. The differential diagnosis with other conditions is sometimes challenging since several disorders may produce
More informationNeuroimaging for dementia diagnosis. Guidance from the London Dementia Clinical Network
Neuroimaging for dementia diagnosis Guidance from the London Dementia Clinical Network Authors Dr Stephen Orleans-Foli Consultant Psychiatrist, West London Mental Health NHS Trust Dr Jeremy Isaacs Consultant
More informationParkinson e decadimento cognitivo. Stelvio Sestini
Parkinson e decadimento cognitivo Stelvio Sestini Patients with PD can develop a spectrum of cognitive symptoms Heterogeneity of cognitive deficits The cognitive symptoms can evolve to dementia (Mov Disorder
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationNon Alzheimer Dementias
Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,
More informationRuolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce
Ruolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce ALESSANDRO MARTORANA UOC NEUROLOGIA-CENTRO ALZHEIMER POLICLINICO TOR VERGATA-UNIVERSITÀ DI ROMA TOR VERGATA
More informationMedicare Program; Reconciling National Coverage Determinations on Positron. Emission Tomography (PET) Neuroimaging for Dementia
This document is scheduled to be published in the Federal Register on 04/11/2018 and available online at https://federalregister.gov/d/2018-07410, and on FDsys.gov BILLING CODE 4120-01-P DEPARTMENT OF
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationUnited Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline
United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline REV 3/24/09 The UCNS Geriatric Neurology examination was established to determine the level of competence
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationNeuroimaging Biomarkers of Neurodegenerative Diseases and Dementia
386 Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia Shannon L. Risacher, PhD 1 Andrew J. Saykin, PsyD 1 1 Center for Neuroimaging, Department of Radiology and Imaging Sciences, and Indiana
More informationDementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings
Dementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings Chapter 4.2 N. Tolboom E.L.G.E. Koedam J.M. Schott M. Yaqub M.A. Blankenstein F. Barkhof Y.A.L. Pijnenburg A.A. Lammertsma
More informationADNI PET CORE. Boston April Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price
ADNI PET CORE Boston April 27 Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price ADNI Florbetapir scan counts Number of Florbetapir scans N SMC EMCI LMCI AD Total
More informationWhat s New in Dementia?
What s New in Dementia? Howard Rosen Professor, Department of Neurology UCSF and Aging Center Disclosure Biogen pharmaceuticals Small grant for clinical trials planning Dementia is a growing source of
More informationCognitive Aging: Defining normal vs. disease?
Cognitive Aging: Defining normal vs. disease? Reisa Sperling, M.D. Harvard Aging Brain Study Center for Alzheimer Research and Treatment Brigham and Women s Hospital Massachusetts General Hospital Harvard
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationThe Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD
The Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD Division of Cognitive and Behavioral Neurology, Brigham and Women s Hospital Co-Director of the Center
More informationMOVEMENT DISORDERS AND DEMENTIA
MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic
More informationConfronting the Clinical Challenges of Frontotemporal Dementia
Confronting the Clinical Challenges of Frontotemporal Dementia A look at FTD s symptoms, pathophysiology, subtypes, as well as the latest from imaging studies. By Zac Haughn, Senior Associate Editor Ask
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationAssessment at the bedside or in the clinic using the history, examination and laboratory tests to distinguish between different types of dementia
Assessment at the bedside or in the clinic using the history, examination and laboratory tests to distinguish between different types of dementia AP Passmore Content Common dementia syndromes (older people)
More informationClinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)
Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following
More informationRe: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities
Public Policy Division 202.393.7737 p 1212 New York Ave NW 866.865.0270 f Suite 800 www.alz.org Washington, DC 20005 Roderick Corriveau, Ph.D. Program Director National Institute of Neurological Disorders
More informationPET ligands and metabolic brain imaging Prof. Karl Herholz
PET ligands Karl Herholz, University of Manchester PET images in this lecture, unless indicated otherwise, are from Max-Planck-Institute for Neurological Research, Cologne, Germany 1 Positron-Emission-Tomography
More informationA Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies
A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies Lynda Mackin, PhD, AGPCNP-BC, CNS University of California San Francisco School of Nursing 1 Alzheimer s
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationMP Amyloid Imaging With Positron Emission Tomography for Alzheimer Disease
Medical Policy MP 6.01.55 BCBSA Ref. Policy: 6.01.55 Last Review: 09/19/2018 Effective Date: 09/19/2018 Section: Radiology Related Policies 2.04.14 Biochemical Markers of Alzheimer Disease 6.01.54 Dopamine
More informationRe: National Coverage Analysis (NCA) for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease
March 15, 2013 Chief Medical Officer for the Director of the Center for Clinical Standards and Quality 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for Beta Amyloid
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationLearnings from Parkinson s disease: Critical role of Biomarkers in successful drug development
Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development Ken Marek Coalition Against Major Diseases and FDA 2014 Annual Scientific Workshop Oct 2014 Disclosure Co-founder
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More information